Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.
GCB-DLBCLs
combination therapies
epigenetics
immune microenvironment
metabolic intermediates
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
10
2021
accepted:
30
11
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
epublish
Résumé
B-cell non-Hodgkin lymphomas (B-NHLs) are highly heterogenous by genetic, phenotypic, and clinical appearance. Next-generation sequencing technologies and multi-dimensional data analyses have further refined the way these diseases can be more precisely classified by specific genomic, epigenomic, and transcriptomic characteristics. The molecular and genetic heterogeneity of B-NHLs may contribute to the poor outcome of some of these diseases, suggesting that more personalized precision-medicine approaches are needed for improved therapeutic efficacy. The germinal center (GC) B-cell like diffuse large B-cell lymphomas (GCB-DLBCLs) and follicular lymphomas (FLs) share specific epigenetic programs. These diseases often remain difficult to treat and surprisingly do not respond advanced immunotherapies, despite arising in secondary lymphoid organs at sites of antigen recognition. Epigenetic dysregulation is a hallmark of GCB-DLBCLs and FLs, with gain-of-function (GOF) mutations in the histone methyltransferase
Identifiants
pubmed: 35071240
doi: 10.3389/fcell.2021.805195
pii: 805195
pmc: PMC8777078
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
805195Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Serganova, Chakraborty, Yamshon, Isshiki, Bucktrout, Melnick, Béguelin and Zappasodi.
Déclaration de conflit d'intérêts
AM has research funds from Janssen, Astra Zeneca, Epizyme, Daiichi Sankyo, and Sanofi, and has consulted for Astra Zeneca, Bristol Myers Squibb, Epizyme, Constellation, ExoTherapeutics, Daiichi Sankyo, and Janssen. W.B. is consulting for Eisai Co., Lrd. RZ is inventor on patent applications related to work on GITR, PD-1, and CTLA-4. RZ is scientific advisory board member of iTEOS Therapeutics, has consulted for Leap Therapeutics and receives grant support from Astra Zeneca and Bristol Myers Squibb.The other authors have no conflicts of interest to disclose.
Références
Oncogene. 2019 Mar;38(11):1802-1814
pubmed: 30361685
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Blood. 2018 Feb 8;131(6):595-604
pubmed: 29158360
PLoS One. 2014 May 16;9(5):e97597
pubmed: 24836297
Blood. 2021 May 20;137(20):2785-2799
pubmed: 33232972
Clin Cancer Res. 2007 Oct 1;13(19):5784-9
pubmed: 17908969
Front Cell Dev Biol. 2020 Sep 03;8:576391
pubmed: 33015069
Haematologica. 2017 May;102(5):903-909
pubmed: 28126962
Cancer Cell. 2013 May 13;23(5):677-92
pubmed: 23680150
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9701-9706
pubmed: 28831000
J Clin Oncol. 2019 Jan 20;37(3):202-212
pubmed: 30523719
Clin Cancer Res. 2020 Jul 1;26(13):3145-3153
pubmed: 32122924
Haematologica. 2021 Mar 01;106(3):718-729
pubmed: 32079690
Cell Metab. 2015 Nov 3;22(5):861-73
pubmed: 26411344
Clin Cancer Res. 2019 Sep 1;25(17):5271-5283
pubmed: 30979734
Blood. 2017 Jan 26;129(4):473-483
pubmed: 28064239
Haematologica. 2015 Mar;100(3):363-9
pubmed: 25425693
Expert Opin Ther Targets. 2007 Jul;11(7):955-65
pubmed: 17614763
J Clin Oncol. 2008 Jan 20;26(3):440-6
pubmed: 18086798
Ann Hematol. 2010 Jan;89(1):25-33
pubmed: 19582455
Blood. 2007 Apr 1;109(7):2871-7
pubmed: 17164341
Blood. 2021 Aug 24;:
pubmed: 34428285
Curr Opin Immunol. 2019 Apr;57:15-22
pubmed: 30342313
Front Immunol. 2015 Sep 01;6:448
pubmed: 26388871
Cancer Discov. 2020 Mar;10(3):440-459
pubmed: 31915197
Onco Targets Ther. 2021 Jan 18;14:481-489
pubmed: 33500624
Oncotarget. 2017 May 29;8(37):61425-61439
pubmed: 28977875
Int J Mol Sci. 2019 Mar 15;20(6):
pubmed: 30884772
J Clin Invest. 2010 Dec 1;120(12):4569-82
pubmed: 21041953
Blood. 2013 Feb 21;121(8):1367-76
pubmed: 23297127
Histopathology. 2012 May;60(6B):E66-75
pubmed: 22394030
Mol Immunol. 2020 Mar;119:35-45
pubmed: 31962268
Semin Immunol. 2018 Feb;35:19-28
pubmed: 29254756
J Clin Oncol. 2009 Mar 20;27(9):1470-6
pubmed: 19224853
Cell. 2017 Jun 29;170(1):142-157.e19
pubmed: 28648661
Nat Rev Genet. 2012 Apr 03;13(5):343-57
pubmed: 22473383
Immunity. 2016 Mar 15;44(3):712
pubmed: 28843072
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Br J Haematol. 2018 Apr;181(2):264-267
pubmed: 28419407
Oncotarget. 2019 Mar 12;10(21):2030-2040
pubmed: 31007846
Exp Mol Med. 2017 Apr 28;49(4):e322
pubmed: 28450738
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Nat Cell Biol. 2017 Nov;19(11):1298-1306
pubmed: 29058720
Cancer Cell. 2011 Dec 13;20(6):728-40
pubmed: 22137796
Medicine (Baltimore). 2017 Apr;96(15):e6398
pubmed: 28403071
Blood. 2016 May 19;127(20):2411-5
pubmed: 26968534
Curr Opin Immunol. 2018 Apr;51:76-82
pubmed: 29547768
Clin Cancer Res. 2010 Jan 15;16(2):637-50
pubmed: 20068089
J Clin Med. 2021 Apr 19;10(8):
pubmed: 33921711
Blood Adv. 2021 Apr 13;5(7):1816-1829
pubmed: 33787861
J Proteome Res. 2017 Mar 3;16(3):1105-1120
pubmed: 28161958
Br J Cancer. 2020 Mar;122(6):895-903
pubmed: 31937921
Immunity. 2019 Aug 20;51(2):310-323.e7
pubmed: 31204070
Blood. 2019 Aug 15;134(7):636-640
pubmed: 31648294
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Exp Mol Med. 2020 Mar;52(3):348-355
pubmed: 32132626
Curr Hematol Malig Rep. 2018 Oct;13(5):383-395
pubmed: 30159703
Med Oncol. 2012 Dec;29(4):2317-22
pubmed: 22198695
Dis Markers. 2010;29(1):47-53
pubmed: 20826917
Cytometry B Clin Cytom. 2012 Mar;82(2):112-9
pubmed: 22076940
Nat Immunol. 2016 Jan;17(1):95-103
pubmed: 26523864
Blood. 2006 Feb 1;107(3):1101-7
pubmed: 16239429
Signal Transduct Target Ther. 2021 Jan 11;6(1):10
pubmed: 33431788
Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):572-580
pubmed: 30106758
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Blood Adv. 2020 Apr 14;4(7):1367-1377
pubmed: 32267932
Hematology. 2017 Aug;22(7):412-418
pubmed: 28281408
Cancer Immunol Res. 2019 May;7(5):696-700
pubmed: 31043393
Clin Cancer Res. 2019 Dec 15;25(24):7331-7339
pubmed: 31471312
PLoS One. 2020 May 22;15(5):e0233449
pubmed: 32442224
N Engl J Med. 2004 Nov 18;351(21):2159-69
pubmed: 15548776
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97
pubmed: 17255259
Haematologica. 2008 Feb;93(2):193-200
pubmed: 18223287
iScience. 2018 Jul 27;5:99-109
pubmed: 30240649
Blood. 2016 Jun 16;127(24):3026-34
pubmed: 27030389
Int Immunol. 2013 Feb;25(2):129-37
pubmed: 23087177
J Clin Oncol. 2017 Dec 10;35(35):3898-3905
pubmed: 28976790
Blood Adv. 2020 Oct 27;4(20):5226-5231
pubmed: 33104794
Cancer Cell. 2016 Aug 8;30(2):197-213
pubmed: 27505670
Blood. 2005 Mar 1;105(5):1851-61
pubmed: 15550490
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
J Clin Oncol. 2006 Dec 1;24(34):5350-7
pubmed: 17135637
Blood Cancer J. 2021 Jan 7;11(1):2
pubmed: 33414466
Blood. 2010 Jan 14;115(2):289-95
pubmed: 19901260
Br J Haematol. 2014 Jun;165(6):768-76
pubmed: 24617454
J Immunol. 2010 Sep 1;185(5):2730-6
pubmed: 20660710
Nat Rev Genet. 2016 Aug;17(8):487-500
pubmed: 27346641
Leuk Lymphoma. 2014 Nov;55(11):2466-76
pubmed: 24397616
Oncoimmunology. 2021 Jul 20;10(1):1928365
pubmed: 34350060
Blood. 2015 Nov 5;126(19):2193-201
pubmed: 26239088
Mol Aspects Med. 2013 Apr-Jun;34(2-3):337-49
pubmed: 23506875
Nat Med. 2015 Oct;21(10):1190-8
pubmed: 26366712
Leukemia. 2021 Mar;35(3):777-786
pubmed: 32601377
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Blood Adv. 2020 Jan 14;4(1):122-126
pubmed: 31917843
Cell Rep. 2015 Sep 29;12(12):2086-98
pubmed: 26365193
Cancer Metab. 2020 Jul 6;8:10
pubmed: 32647571
Immunity. 2017 Apr 18;46(4):596-608
pubmed: 28410989
Blood Adv. 2019 Feb 26;3(4):531-540
pubmed: 30770362
Oncoimmunology. 2017 Mar 3;6(4):e1295202
pubmed: 28507804
PLoS One. 2014 Jun 03;9(6):e97090
pubmed: 24892698
Nat Immunol. 2020 Mar;21(3):331-342
pubmed: 32066950
Nat Commun. 2017 Oct 26;8(1):1141
pubmed: 29070843
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11404-11409
pubmed: 29073064
Gene. 2017 Sep 5;627:337-342
pubmed: 28669924
Blood. 2021 Feb 4;137(5):637-645
pubmed: 32870269
Front Immunol. 2016 Feb 16;7:52
pubmed: 26909082
Nature. 2011 Mar 17;471(7338):377-81
pubmed: 21368758
Ann Oncol. 2008 May;19(5):964-9
pubmed: 18296419
Cancer Cell. 2019 Jun 10;35(6):916-931.e9
pubmed: 31185214
Cancer Discov. 2020 Dec;10(12):1912-1933
pubmed: 32887696
J Clin Invest. 2012 Apr;122(4):1271-82
pubmed: 22426209
Mol Cell. 2005 Sep 16;19(6):857-64
pubmed: 16140033
Immunity. 2019 Aug 20;51(2):204-206
pubmed: 31433965
Pathol Int. 2015 Apr;65(4):170-6
pubmed: 25707506
Blood. 2019 Mar 7;133(10):1119-1129
pubmed: 30591526
Curr Opin Immunol. 2020 Apr;63:21-28
pubmed: 31794945
Nat Genet. 2011 Jul 31;43(9):830-7
pubmed: 21804550
J Clin Invest. 2020 Apr 1;130(4):1576-1585
pubmed: 32039913
Immunol Rev. 2019 Mar;288(1):214-239
pubmed: 30874354
Cancer Discov. 2013 Sep;3(9):1002-19
pubmed: 23955273
Immunity. 2019 Sep 17;51(3):535-547.e9
pubmed: 31519498
Leukemia. 2020 Aug;34(8):2184-2197
pubmed: 32060403
Lancet Oncol. 2018 May;19(5):649-659
pubmed: 29650362
J Clin Oncol. 2019 Apr 10;37(11):912-922
pubmed: 30742566
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34127544
Nat Immunol. 2017 Mar;18(3):303-312
pubmed: 28114292
Mol Ther. 2021 Sep 1;29(9):2640-2659
pubmed: 34365035
Blood. 2004 Jun 1;103(11):4251-8
pubmed: 14976040
J Clin Oncol. 2001 Feb 1;19(3):720-6
pubmed: 11157023
Cancer Immunol Res. 2019 Mar;7(3):355-362
pubmed: 30659053
Clin Cancer Res. 2018 Feb 15;24(4):870-881
pubmed: 29217528
Molecules. 2018 Mar 02;23(3):
pubmed: 29498635
Cell. 2016 Oct 6;167(2):405-418.e13
pubmed: 27693350
Annu Rev Cancer Biol. 2021 Mar;5(1):235-257
pubmed: 34109280
Blood. 2006 Jul 1;108(1):311-8
pubmed: 16543468
Cancer Res. 2017 Sep 15;77(18):5118-5128
pubmed: 28716895
Nature. 2017 Mar 30;543(7647):723-727
pubmed: 28329770
Leuk Res. 2010 Jul;34(7):899-905
pubmed: 20381863
Immunity. 2007 Aug;27(2):190-202
pubmed: 17723214
Blood. 2021 Aug 5;138(5):370-381
pubmed: 33786580
Blood Adv. 2021 May 25;5(10):2467-2480
pubmed: 33999145
Haematologica. 2015 Feb;100(2):238-45
pubmed: 25381134
Blood. 2008 Jun 1;111(11):5359-70
pubmed: 18305220
J Immunol. 2007 Jun 1;178(11):6840-8
pubmed: 17513732
Immunity. 2016 Sep 20;45(3):471-482
pubmed: 27653600
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Cancer Discov. 2017 Jan;7(1):38-53
pubmed: 27733359
Nature. 2015 Nov 12;527(7577):249-53
pubmed: 26503055
J Clin Oncol. 2019 Feb 20;37(6):481-489
pubmed: 30620669
Oncotarget. 2017 Nov 30;8(67):112116-112131
pubmed: 29340116
Bioessays. 2017 Nov;39(11):
pubmed: 28961325
Nat Commun. 2018 Jan 15;9(1):222
pubmed: 29335468
Sci Rep. 2016 Jul 28;6:30347
pubmed: 27464733
Cancer Discov. 2021 Jun;11(6):1468-1489
pubmed: 33541860
Cell Oncol (Dordr). 2019 Jun;42(3):303-318
pubmed: 30790227
Blood. 2017 May 11;129(19):2645-2656
pubmed: 28288979
Nat Rev Dis Primers. 2019 Dec 12;5(1):83
pubmed: 31831752
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25
pubmed: 25713363
EMBO J. 2015 Jul 2;34(13):1773-85
pubmed: 25979827
Nat Struct Mol Biol. 2013 Oct;20(10):1147-55
pubmed: 24096405
N Engl J Med. 2014 Mar 13;370(11):1008-18
pubmed: 24450858
Lancet Oncol. 2021 May;22(5):678-689
pubmed: 33848462
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Cancer Discov. 2019 Sep;9(9):1228-1247
pubmed: 31189531
Molecules. 2019 Jun 26;24(13):
pubmed: 31248049
Nature. 2011 Mar 10;471(7337):189-95
pubmed: 21390126
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
Oncotarget. 2017 Feb 21;8(8):14017-14028
pubmed: 28147336
Leukemia. 2016 Mar;30(3):605-16
pubmed: 26500140
Cell Rep. 2013 Aug 15;4(3):578-88
pubmed: 23911289
Blood. 2020 Jul 16;136(3):299-312
pubmed: 32325489
J Clin Oncol. 2021 May 20;39(15):1609-1618
pubmed: 33683917
Cancer Cell. 2018 Apr 9;33(4):581-598
pubmed: 29634946
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):
pubmed: 34050029
Blood. 2006 Nov 1;108(9):2957-64
pubmed: 16825494
Immunity. 2013 Nov 14;39(5):819-32
pubmed: 24238339
Immunity. 2015 Feb 17;42(2):227-238
pubmed: 25680271
Nat Biotechnol. 2014 Feb;32(2):158-68
pubmed: 24441474
Cell. 2002 Oct 4;111(1):41-50
pubmed: 12372299
Mol Cell Proteomics. 2021;20:100006
pubmed: 33203747
Blood. 2016 Feb 18;127(7):869-81
pubmed: 26702065
Cell Biosci. 2020 Dec 11;10(1):143
pubmed: 33308321
J Cell Mol Med. 2021 Jul;25(14):7066-7077
pubmed: 34128320
Blood Adv. 2021 Apr 27;5(8):2256-2263
pubmed: 33904892
Cell Rep. 2014 Jan 16;6(1):130-40
pubmed: 24388756
Clin Cancer Res. 2019 Dec 1;25(23):6995-7003
pubmed: 31444250
BMC Cancer. 2019 Nov 6;19(1):1049
pubmed: 31694577
Cancer Genet. 2015 May;208(5):178-91
pubmed: 25794446
Blood. 2013 Jan 31;121(5):734-44
pubmed: 23223433
Nat Genet. 2014 Feb;46(2):176-181
pubmed: 24362818
Nat Commun. 2017 Oct 12;8(1):877
pubmed: 29026085
Blood. 2004 Dec 15;104(13):4088-96
pubmed: 15331443
BMC Med. 2016 Oct 17;14(1):159
pubmed: 27745550
Haematologica. 2015 Mar;100(3):357-62
pubmed: 25596263
EMBO Rep. 2021 Jul 5;22(7):e52774
pubmed: 34159701
Leuk Lymphoma. 2016 Oct;57(10):2359-69
pubmed: 26758422
Virchows Arch. 2014 Sep;465(3):351-8
pubmed: 25011996
Haematologica. 2017 Aug;102(8):1413-1423
pubmed: 28411252
Cancer Cell. 2012 Oct 16;22(4):547-60
pubmed: 23079663
Eur J Cancer. 2016 Nov;68:134-147
pubmed: 27755997
Cancer Res. 2021 Feb 15;81(4):860-872
pubmed: 33361394
Cancers (Basel). 2015 Apr 30;7(2):736-62
pubmed: 25941795
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947
Cell Metab. 2019 Jun 4;29(6):1243-1257.e10
pubmed: 30827861
J Clin Oncol. 2019 Jan 20;37(3):190-201
pubmed: 30523716
Clin Cancer Res. 2000 Oct;6(10):3904-9
pubmed: 11051236
Nature. 2019 Oct;574(7779):575-580
pubmed: 31645732
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6666-72
pubmed: 18006767
Ann Oncol. 2017 Sep 1;28(9):2169-2178
pubmed: 28633365
J Clin Oncol. 2016 Apr 1;34(10):1104-11
pubmed: 26884582
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Clin Invest. 2013 Dec;123(12):5009-22
pubmed: 24200695
Oncoimmunology. 2015 Feb 3;4(5):e1002728
pubmed: 26155390
J Clin Invest. 2018 Aug 31;128(9):3813-3818
pubmed: 29905573
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
J Clin Oncol. 2011 Mar 20;29(9):1198-203
pubmed: 21300924
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Nat Genet. 2010 Feb;42(2):181-5
pubmed: 20081860
Curr Opin Chem Biol. 2016 Feb;30:52-60
pubmed: 26629854
Int J Immunopathol Pharmacol. 2005 Jul-Sep;18(3):431-43
pubmed: 16164826
Mol Cell. 2006 Aug 4;23(3):377-87
pubmed: 16885027
Immunity. 2021 Jan 12;54(1):116-131.e10
pubmed: 33271120
Nat Commun. 2021 Jan 18;12(1):409
pubmed: 33462245
Cancer Cell. 2020 May 11;37(5):655-673.e11
pubmed: 32396861
J Immunol. 2013 Jun 15;190(12):6681-93
pubmed: 23686488
Blood. 2005 Sep 15;106(6):2169-74
pubmed: 15933054
Nat Rev Cancer. 2016 Nov;16(11):694-707
pubmed: 27634449
Nat Med. 2015 Oct;21(10):1199-208
pubmed: 26366710
Science. 1998 Dec 18;282(5397):2263-6
pubmed: 9856951
Leukemia. 2006 Jul;20(7):1300-3
pubmed: 16673020
Blood Cancer J. 2015 Feb 20;5:e281
pubmed: 25700246
Clin Cancer Res. 2020 Oct 1;26(19):5217-5231
pubmed: 32631956
Cell Rep. 2018 Jun 12;23(11):3262-3274
pubmed: 29898397
Semin Immunol. 2021 Feb;52:101480
pubmed: 34006473
Cancer Discov. 2019 Apr;9(4):546-563
pubmed: 30705065
Lancet Oncol. 2020 Nov;21(11):1433-1442
pubmed: 33035457
Am J Hematol. 2018 Aug;93(4):486-493
pubmed: 29266344
Cancer Cell. 2020 Apr 13;37(4):599-617.e7
pubmed: 32243837
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Nat Immunol. 2019 Jan;20(1):86-96
pubmed: 30538335
Cell Rep. 2019 Nov 19;29(8):2321-2337.e7
pubmed: 31747604
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Cancer Discov. 2017 Mar;7(3):322-337
pubmed: 28069569